Dermatology

Guselkumab also showed promising results in the treatment of psoriatic arthritis, with improved disease activity in joints and across multiple domains through 1 year.

This is the first approval for secukinumab in a pediatric population in the United States for severe plaque psoriasis.

Both health care providers and the general public said skin dryness is a major obstacle for consistent hand hygiene practices.

The study authors said that treating the condition has been difficult until now due to a lack of FDA-approved therapies.

Study participants who fasted 2 days per week reported fewer scaling and thickening, with 30% also reporting a decrease in itching associated with psoriasis.

Although therapeutics and vaccines for COVID-19 have dominated the news in the last year, development of other drugs has continued.

The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.

Some drugs commonly used for psoriasis can increase the risk of cardiovascular diseases, whereas other treatments can reduce the risk.

With a 1-hour infusion and lower infusion volume, oritavancin could minimize health system costs to treat these infections and improve efficiency in clinical practice.

Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23.

Tildrakizumab is an IL-23 inhibitor indicated for adults with moderate-to-severe plaque psoriasis and is under investigation for PsA.

What is causing a patient's outbreak of psoriasis?

Top news of the day across the health care landscape.

A phase 3 trial evaluated dupilumab (Dupixent, Regeneron and Sanofi) in children from 6 to 11 years of age with severe atopic dermatitis.

Top news of the day from across the health care landscape.

Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.

The study focused on the comparative risk of infection across 7 systemic biologics.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

A head-to-head trial evaluated quality of life improvements in patients with moderate-to-severe psoriasis treated with secukinumab (Cosentyx) or ustekinumab (Stelara).

Top news of the week from Specialty Pharmacy Times.

With this approval, dupilumab (Dupixent) offers a biologic therapy option for patients 12 to 17 years of age who have moderate-to-severe atopic dermatitis.

Approximately 1.7 million insured US patients are burdened with moderate to severe plaque psoriasis.